Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
57 people get UCBJF.PK articles and Market Currents by email alert.
Get email alerts on UCBJF.PK »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
Rheumatoid Arthritis Slip-Up Unlikely To Affect Resurgent UCB SharesEP Vantage • Fri, Sep 28, 2012 -
-
-
-
-
Failure to Launch for Last Year's Big Pharma and Biotech HopesEP Vantage • Fri, Feb 13, 2009
-
Biotech Day In Review: BioSimilar Cancer Drug Enters TrialCentient Biotech Investor • Thu, Mar 22, 2007 -
-
Biotech Day in Review: ImClone Chooses to Go It AloneCentient Biotech Investor • Wed, Feb 7, 2007
To learn more about Seeking Alpha Pro, click here.
There are no Focus articles on UCBJF.PK.
-
-
Rheumatoid Arthritis Slip-Up Unlikely To Affect Resurgent UCB SharesEP Vantage • Fri, Sep 28, 2012
-
-
-
-
-
Failure to Launch for Last Year's Big Pharma and Biotech HopesEP Vantage • Fri, Feb 13, 2009
-
Biotech Day In Review: BioSimilar Cancer Drug Enters TrialCentient Biotech Investor • Thu, Mar 22, 2007
-
-
Biotech Day in Review: ImClone Chooses to Go It AloneCentient Biotech Investor • Wed, Feb 7, 2007
There are no Transcripts on UCBJF.PK.
There are no News articles on UCBJF.PK.
UCBJF.PK vs. ETF Alternatives
Company Description
Currently, there's no company description for UCBJF.PK.
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Wednesday, December 28, 2011, 3:02 AM Immunomedics (IMMU) and UCB (UCBJF.PK) tweak their pact for developing and marketing epratuzumab, a drug for lupus, cancer and other diseases. The changes predominately concern marketing rights. UCB also gets a five-year warrant to buy 1M Immunomedics shares at $8 apiece; IMMU currently at $3.37. Comment! [Healthcare]
Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.